UA82472C2 - Трансдермальная фармацевтическая композиция, которая содержит ацетилсалициловую кислоту, для лечения кальцификации - Google Patents
Трансдермальная фармацевтическая композиция, которая содержит ацетилсалициловую кислоту, для лечения кальцификации Download PDFInfo
- Publication number
- UA82472C2 UA82472C2 UA20040604708A UA20040604708A UA82472C2 UA 82472 C2 UA82472 C2 UA 82472C2 UA 20040604708 A UA20040604708 A UA 20040604708A UA 20040604708 A UA20040604708 A UA 20040604708A UA 82472 C2 UA82472 C2 UA 82472C2
- Authority
- UA
- Ukraine
- Prior art keywords
- acetylsalicylic acid
- composition according
- carbonate
- alkali metal
- differs
- Prior art date
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
- 208000004434 Calcinosis Diseases 0.000 title abstract description 13
- 230000002308 calcification Effects 0.000 title abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 42
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims abstract description 9
- 150000001340 alkali metals Chemical class 0.000 claims abstract description 9
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 7
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims abstract description 5
- 150000008041 alkali metal carbonates Chemical class 0.000 claims abstract description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 6
- -1 alkali metal bicarbonate Chemical class 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 5
- 239000012752 auxiliary agent Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 239000003158 myorelaxant agent Substances 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 150000003512 tertiary amines Chemical class 0.000 claims description 3
- 206010040880 Skin irritation Diseases 0.000 claims description 2
- 239000003435 antirheumatic agent Substances 0.000 claims description 2
- 239000003589 local anesthetic agent Substances 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 2
- 230000036556 skin irritation Effects 0.000 claims description 2
- 231100000475 skin irritation Toxicity 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 abstract description 6
- 239000001099 ammonium carbonate Substances 0.000 abstract description 6
- 235000012501 ammonium carbonate Nutrition 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 10
- 230000004060 metabolic process Effects 0.000 description 10
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 210000001503 joint Anatomy 0.000 description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 5
- 229960004889 salicylic acid Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- FMBVHKPWDJQLNO-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-5-nitroindazole Chemical compound N1=CC2=CC([N+](=O)[O-])=CC=C2N1CC1=CC=CC(F)=C1 FMBVHKPWDJQLNO-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 3
- 239000001639 calcium acetate Substances 0.000 description 3
- 235000011092 calcium acetate Nutrition 0.000 description 3
- 229960005147 calcium acetate Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 150000001243 acetic acids Chemical class 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000004579 marble Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229940035363 muscle relaxants Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 150000003870 salicylic acids Chemical class 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000623906 Lytta vesicatoria Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940068372 acetyl salicylate Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- AVVIDTZRJBSXML-UHFFFAOYSA-L calcium;2-carboxyphenolate;dihydrate Chemical compound O.O.[Ca+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O AVVIDTZRJBSXML-UHFFFAOYSA-L 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относится к фармацевтике, в частности к трансдермальной фармацевтической композиции, содержащей ацетилсалициловую кислоту вместе с растворителем и/или другим вспомогательным агентом. Композиция, согласно изобретению, также содержит карбонат и/или гидрокарбонат щелочного металла и/или аммония, в количестве, эквивалентном 0,01- диоксида углерода на ацетилсалициловой кислоты, и буфер с рН 5,5-7.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0104968A HU227496B1 (en) | 2001-11-16 | 2001-11-16 | Transdermal pharmaceutical composition containing aspirine for the treatment of sclerosis |
| PCT/HU2002/000112 WO2003041743A1 (en) | 2001-11-16 | 2002-10-31 | Aspirin-containing transdermal pharmaceutical composition for the treatment of calcification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA82472C2 true UA82472C2 (ru) | 2008-04-25 |
Family
ID=50701118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20040604708A UA82472C2 (ru) | 2001-11-16 | 2002-10-31 | Трансдермальная фармацевтическая композиция, которая содержит ацетилсалициловую кислоту, для лечения кальцификации |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050004084A1 (ru) |
| EP (1) | EP1446160B1 (ru) |
| CN (1) | CN100342913C (ru) |
| AT (1) | ATE390934T1 (ru) |
| CA (1) | CA2465334A1 (ru) |
| DE (1) | DE60225939D1 (ru) |
| EA (1) | EA200400650A1 (ru) |
| HK (1) | HK1071056A1 (ru) |
| HU (1) | HU227496B1 (ru) |
| UA (1) | UA82472C2 (ru) |
| WO (1) | WO2003041743A1 (ru) |
| ZA (1) | ZA200403220B (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050074503A1 (en) * | 2003-10-05 | 2005-04-07 | Brilman Yakov Yevseyevich | Bilious balsam |
| WO2011076401A1 (de) | 2009-12-23 | 2011-06-30 | Holger Schankin | Acetylsalicylsäure-haltige, im wesentlichen wasserfreie pharmazeutische zusammensetzungen |
| ES2525766B1 (es) * | 2013-06-24 | 2015-10-13 | Linguaversal S.L. | Sistema y método para mejorar la percepción de los sonidos de un idioma extranjero |
| EP4112043A1 (en) * | 2021-06-30 | 2023-01-04 | GSK Consumer Healthcare SARL | Nano-complex composition comprising diclofenac |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL44774A (en) * | 1974-05-06 | 1977-07-31 | Baron E | Pharmaceutical composition containing acetyl salicyclic acid |
| US4275059A (en) * | 1977-03-28 | 1981-06-23 | The Procter & Gamble Company | Salicylate anti-inflammatory composition |
| US5037648A (en) * | 1989-11-20 | 1991-08-06 | Joiner Evelyn S | Skin conditioning preparation having a pH above 7, method and method of making |
| US5140068A (en) * | 1990-04-27 | 1992-08-18 | The B. F. Goodrich Company | Epoxy resin systems modified with low viscosity statistical monofunctional reactive polymers |
| US5176918A (en) * | 1990-12-20 | 1993-01-05 | Jones Jeffry L | Topical medicament |
| US5612382A (en) * | 1994-07-15 | 1997-03-18 | Frances B. Fike | Composition for percutaneous absorption of pharmaceutically active ingredients |
| JPH1112177A (ja) * | 1997-06-25 | 1999-01-19 | Teikoku Seiyaku Co Ltd | 安定なアスピリン含有外用製剤 |
| US6419935B1 (en) * | 1998-07-30 | 2002-07-16 | L'oreal S.A. | Cosmetic skin treatment method and cleansing treatment patch |
| HU9902296D0 (en) * | 1999-07-07 | 1999-10-28 | Dardai | Pharmaceutical composition for treating caltification |
| US6645520B2 (en) * | 1999-12-16 | 2003-11-11 | Dermatrends, Inc. | Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers |
-
2001
- 2001-11-16 HU HU0104968A patent/HU227496B1/hu not_active IP Right Cessation
-
2002
- 2002-10-31 UA UA20040604708A patent/UA82472C2/ru unknown
- 2002-10-31 EP EP02777584A patent/EP1446160B1/en not_active Expired - Lifetime
- 2002-10-31 EA EA200400650A patent/EA200400650A1/ru unknown
- 2002-10-31 US US10/495,778 patent/US20050004084A1/en not_active Abandoned
- 2002-10-31 DE DE60225939T patent/DE60225939D1/de not_active Expired - Lifetime
- 2002-10-31 CA CA002465334A patent/CA2465334A1/en not_active Abandoned
- 2002-10-31 AT AT02777584T patent/ATE390934T1/de not_active IP Right Cessation
- 2002-10-31 WO PCT/HU2002/000112 patent/WO2003041743A1/en active IP Right Grant
- 2002-10-31 CN CNB028227085A patent/CN100342913C/zh not_active Expired - Fee Related
-
2004
- 2004-04-29 ZA ZA200403220A patent/ZA200403220B/en unknown
-
2005
- 2005-02-18 HK HK05101417A patent/HK1071056A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003041743A1 (en) | 2003-05-22 |
| US20050004084A1 (en) | 2005-01-06 |
| CA2465334A1 (en) | 2003-05-22 |
| EA200400650A1 (ru) | 2004-10-28 |
| DE60225939D1 (de) | 2008-05-15 |
| HK1071056A1 (en) | 2005-07-08 |
| ATE390934T1 (de) | 2008-04-15 |
| EP1446160A1 (en) | 2004-08-18 |
| EP1446160B1 (en) | 2008-04-02 |
| ZA200403220B (en) | 2004-07-28 |
| HUP0104968D0 (en) | 2002-01-28 |
| HUP0104968A2 (hu) | 2004-05-28 |
| CN1610558A (zh) | 2005-04-27 |
| CN100342913C (zh) | 2007-10-17 |
| HU227496B1 (en) | 2011-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4296104A (en) | Therapeutic dimethyl sulfoxide composition and methods of use | |
| JP2953625B2 (ja) | 薬剤／浸透促進組成物に関連する皮膚刺激を低下させる方法 | |
| ES2320054T3 (es) | Composiciones farmaceuticas que comprenden un surfactante anfoterico, un alcohol cetilico polipropoxilado y farmaco polar. | |
| US4021572A (en) | Prophylactic and therapeutic treatment of acne vulgaris utilizing lactamides and quaternary ammonium lactates | |
| ES2429443T3 (es) | Suministro transdérmico de sustancias beneficiosas efectuado mediante un entorno de fuerza iónica elevada | |
| US5728391A (en) | Hyaluronic acid and its salt for treating skin diseases | |
| PT1510213E (pt) | Sistemas de melhoramento de penetração e reduzida irritação incluíndo testosterona | |
| BRPI0520076B1 (pt) | preparação externa para pele, drogas preventivas/melhoradoras para aspereza de pele, para pele seca, e para rugas/manchas, métodos para prevenir/melhorar aspereza de pele, pele seca, e rugas/manchas, droga melhoradora de dermatite atópica, método para melhorar dermatite atópica, e, conjunto de preparações externas para pele | |
| US20050137164A1 (en) | Diclofenac compositions for the treatment of skin disorders | |
| KR20010041527A (ko) | 국소적 항바이러스성 조성물로서 무기 아질산염 및유기산의 조성 | |
| BR0014895A (pt) | Formulação lìquida estável, processo para a preparação da mesma, uso da mesma, uso de polietileno glicol e sal de sódio ou potássio de um inibidor h+, k+-atpase, e, método para tratar doenças gastrointestinais | |
| JPH08175986A (ja) | 経皮活性を示す５−アミノレブリン酸含有薬学組成物 | |
| WO2005039464A1 (en) | Transdermal high and low molecular weight compounds | |
| Kyuki et al. | Anti-inflammatory effect of diclofenac-sodium ointment (cream) in topical application | |
| UA82472C2 (ru) | Трансдермальная фармацевтическая композиция, которая содержит ацетилсалициловую кислоту, для лечения кальцификации | |
| CA2422531C (en) | Topical analgesic compositions containing aliphatic polyamines and methods of using same | |
| JPH09504018A (ja) | 抗掻痒薬としてのイブプロフェンおよびフルルビプロフェン | |
| JP2016513686A (ja) | フルチカゾンの経皮製剤 | |
| ES2314365T3 (es) | Utilizacion de una composicion que comprende oxido de vitamina k1 o un derivado del mismo para el tratamiento y/o la prevencion de lesiones dermatologicas en los mamiferos. | |
| JPS62155214A (ja) | 炎症治療薬及びそれによる炎症治療方法 | |
| ES2237457T3 (es) | Composiciones farmaceuticas y/o cosmeticas. | |
| NL1018862C2 (nl) | Behandeling van brandwonden. | |
| CZ304915B6 (cs) | Využití alaptidu jako modifikátoru transdermální penetrace ve farmaceutických kompozicích pro humánní a veterinární aplikace obsahující nesteroidní antiflogistika a/nebo antipyretika-analgetika | |
| BRPI0902144A2 (pt) | processo para preparar uma composição farmacêutica sólida, de administração por via oral que contém os prìncipios ativos glicosamina e meloxicam e uso da associação entre glicosamina e meloxicam | |
| PT1423126E (pt) | Tratamento de condições hiperproliferativas de superfícies corporais |